NI201300008A - THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER - Google Patents
THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMERInfo
- Publication number
- NI201300008A NI201300008A NI201300008A NI201300008A NI201300008A NI 201300008 A NI201300008 A NI 201300008A NI 201300008 A NI201300008 A NI 201300008A NI 201300008 A NI201300008 A NI 201300008A NI 201300008 A NI201300008 A NI 201300008A
- Authority
- NI
- Nicaragua
- Prior art keywords
- conjugate
- formula
- polyethylene glycol
- interferon
- represented
- Prior art date
Links
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 2
- 208000031951 Primary immunodeficiency Diseases 0.000 abstract 2
- 206010054979 Secondary immunodeficiency Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079322 interferon Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención está relacionada a la industria farmacéutica y medicina, en particular, al nuevo PEG - interferón derivados y al descubrimiento de un conjugado nuevo funcional, altamente estable de interferón a polietileno glicol con una actividad interferón alfa, con inmunogenicidad reducida, con efectos biológicos prolongados y parámetros fármaco - kinéticos mejorados de fórmula general (I). También la invención está relacionada a drogas conteniendo el declarado conjugado de la fórmula (1), composiciones farmacéuticas conteniendo PEG - IFN conjugado y terapéuticamente aceptable excipientes ideales para el tratamiento de infecciones virales y cáncer, también enfermedades asociadas con inmunodeficiencia primaria o secundaria. La invención está relacionada al uso de conjugado de fórmula (1) en productos medicinales, los cuales tienen actividad antiviral, antiproliferativa e inmunomodulatoria, aproximaciones y/o tratamiento de enfermedades asociadas con inmunodeficiencia primaria o secundaria de conjugado de fórmula (1) y al contenedor con tal composición farmacéutica.The invention is related to the pharmaceutical industry and medicine, in particular, to the new PEG-interferon derivatives and to the discovery of a new functional, highly stable conjugate of interferon to polyethylene glycol with an alpha interferon activity, with reduced immunogenicity, with prolonged biological effects. and improved drug-kinetic parameters of general formula (I). The invention is also related to drugs containing the declared conjugate of formula (1), pharmaceutical compositions containing PEG-IFN conjugated and therapeutically acceptable excipients ideal for the treatment of viral infections and cancer, also diseases associated with primary or secondary immunodeficiency. The invention is related to the use of conjugate of formula (1) in medicinal products, which have antiviral, antiproliferative and immunomodulatory activity, approaches and / or treatment of diseases associated with primary or secondary immunodeficiency of conjugate of formula (1) and to the container with such a pharmaceutical composition.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010129824/10A RU2447083C1 (en) | 2010-07-20 | 2010-07-20 | NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NαH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201300008A true NI201300008A (en) | 2014-05-26 |
Family
ID=45497062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201300008A NI201300008A (en) | 2010-07-20 | 2013-01-18 | THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER |
Country Status (20)
| Country | Link |
|---|---|
| KR (1) | KR101586372B1 (en) |
| CN (1) | CN102617736B (en) |
| AR (1) | AR087227A1 (en) |
| BR (1) | BRPI1101565A2 (en) |
| CO (1) | CO6680611A2 (en) |
| CR (1) | CR20130021A (en) |
| CU (1) | CU24193B1 (en) |
| DO (1) | DOP2013000002A (en) |
| EA (1) | EA020257B1 (en) |
| EC (1) | ECSP13012398A (en) |
| MX (1) | MX2011007458A (en) |
| MY (1) | MY168784A (en) |
| NI (1) | NI201300008A (en) |
| PE (1) | PE20131034A1 (en) |
| PH (1) | PH12012502425A1 (en) |
| RU (1) | RU2447083C1 (en) |
| SG (1) | SG187117A1 (en) |
| UA (1) | UA99766C2 (en) |
| UY (1) | UY33525A (en) |
| WO (1) | WO2012011836A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2515913C1 (en) * | 2013-03-22 | 2014-05-20 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") | HYBRID PROTEIN HAVING PROLONGED ACTION, BASED ON RECOMBINANT HUMAN INTERFERON ALPHA-2 (VARIANTS), METHOD OF ITS PRODUCTION AND STRAIN OF Saccharomyces cerevisiae FOR IMPLEMENTING THIS METHOD (VERSIONS) |
| EA021643B1 (en) * | 2013-03-28 | 2015-07-30 | Илья Александрович МАРКОВ | Monopegylated interferon-alpha of linear structure and a pharmaceutical composition for preparing a medicament having interferon-alpha activity |
| EA021610B1 (en) * | 2013-03-28 | 2015-07-30 | Илья Александрович МАРКОВ | Liquid antiviral formulation |
| CN103463623B (en) * | 2013-09-03 | 2015-09-09 | 长春海伯尔生物技术有限责任公司 | A kind of Peg-IFN alpha-2b injection and preparation method thereof |
| RU2554761C1 (en) * | 2014-05-13 | 2015-06-27 | Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" | Anti-enteroviral and immunostimulating agent |
| RU2572800C1 (en) * | 2014-09-22 | 2016-01-20 | Закрытое Акционерное Общество "Биокад" | New formulation containing polyethylene glycol (peg) conjugated interferon alpha-2beta characterised by less painful administration |
| EA029498B1 (en) * | 2015-11-24 | 2018-04-30 | Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) | ANTI-TUMOUR DRUG BASED ON RECOMBINANT INTERFERON ALPHA-2b IN THE FORM OF MICROPARTICLES FOR PARENTERAL ADMINISTRATION |
| RU2678332C1 (en) | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof |
| AU2021258734A1 (en) * | 2020-04-20 | 2023-01-05 | Altum Pharmaceuticals Inc. | Recombinant interferon |
| CN114392237B (en) * | 2021-12-28 | 2024-02-02 | 上海允英生物医药科技有限公司 | Freeze-dried virus preparation and preparation method thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
| TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| EA200500475A1 (en) * | 2002-09-09 | 2005-10-27 | Нектар Терапеутикс Ал, Корпорейшн | WATER-SOLUBLE POLYMERIC ALCANALS |
| RU2311930C2 (en) * | 2004-04-30 | 2007-12-10 | Закрытое акционерное общество "ВЕРОФАРМ" | Pagylated interferon against viral infection |
| EP1771197A2 (en) * | 2004-06-30 | 2007-04-11 | Egen Corporation | Pegylated interferon alpha-1b |
| DE602006013151D1 (en) * | 2005-07-19 | 2010-05-06 | Nektar Therapeutics | METHOD FOR PRODUCING POLYMERMALIMIDES |
| WO2007149594A2 (en) * | 2006-06-23 | 2007-12-27 | Quintessence Biosciences, Inc. | Modified ribonucleases |
| CN101491682A (en) * | 2008-04-30 | 2009-07-29 | 北京凯正生物工程发展有限责任公司 | PEG-IFN omega conjugate and preparation technique thereof |
| CN101591387A (en) * | 2008-05-28 | 2009-12-02 | 中国人民解放军军事医学科学院微生物流行病研究所 | Pegylated recombinant human interferon omega conjugate |
| CN101514229B (en) * | 2009-04-03 | 2012-05-09 | 海南四环心脑血管药物研究院有限公司 | Human interferon alpha derivative and polyethylene glycol modified substance thereof |
-
2010
- 2010-07-20 RU RU2010129824/10A patent/RU2447083C1/en active
- 2010-09-24 WO PCT/RU2010/000529 patent/WO2012011836A1/en not_active Ceased
- 2010-09-24 SG SG2013003801A patent/SG187117A1/en unknown
- 2010-09-24 CU CUP2013000013A patent/CU24193B1/en active IP Right Grant
- 2010-09-24 PH PH1/2012/502425A patent/PH12012502425A1/en unknown
- 2010-09-24 PE PE2013000084A patent/PE20131034A1/en not_active Application Discontinuation
- 2010-09-24 MY MYPI2013000216A patent/MY168784A/en unknown
- 2010-09-24 KR KR1020137001858A patent/KR101586372B1/en not_active Expired - Fee Related
- 2010-12-15 UA UAA201015114A patent/UA99766C2/en unknown
-
2011
- 2011-04-01 BR BRPI1101565-9A patent/BRPI1101565A2/en not_active IP Right Cessation
- 2011-06-21 EA EA201100809A patent/EA020257B1/en not_active IP Right Cessation
- 2011-07-12 MX MX2011007458A patent/MX2011007458A/en active IP Right Grant
- 2011-07-19 CN CN201110214149.6A patent/CN102617736B/en not_active Expired - Fee Related
- 2011-07-19 AR ARP110102606A patent/AR087227A1/en unknown
- 2011-07-20 UY UY0001033525A patent/UY33525A/en unknown
-
2013
- 2013-01-04 DO DO2013000002A patent/DOP2013000002A/en unknown
- 2013-01-18 EC ECSP13012398 patent/ECSP13012398A/en unknown
- 2013-01-18 CR CR20130021A patent/CR20130021A/en unknown
- 2013-01-18 CO CO13009157A patent/CO6680611A2/en unknown
- 2013-01-18 NI NI201300008A patent/NI201300008A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201100809A1 (en) | 2012-01-30 |
| CU24193B1 (en) | 2016-09-30 |
| MX2011007458A (en) | 2012-01-19 |
| CN102617736A (en) | 2012-08-01 |
| BRPI1101565A2 (en) | 2012-12-04 |
| MY168784A (en) | 2018-12-04 |
| RU2447083C1 (en) | 2012-04-10 |
| DOP2013000002A (en) | 2013-09-15 |
| CN102617736B (en) | 2015-11-25 |
| CO6680611A2 (en) | 2013-05-31 |
| UA99766C2 (en) | 2012-09-25 |
| KR20130056885A (en) | 2013-05-30 |
| SG187117A1 (en) | 2013-02-28 |
| AR087227A1 (en) | 2014-03-12 |
| CU20130013A7 (en) | 2013-04-19 |
| ECSP13012398A (en) | 2013-05-31 |
| EA020257B1 (en) | 2014-09-30 |
| UY33525A (en) | 2012-02-29 |
| KR101586372B1 (en) | 2016-01-18 |
| HK1170504A1 (en) | 2013-03-01 |
| CR20130021A (en) | 2013-02-20 |
| RU2010129824A (en) | 2012-01-27 |
| WO2012011836A1 (en) | 2012-01-26 |
| PH12012502425A1 (en) | 2013-07-08 |
| PE20131034A1 (en) | 2013-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201300008A (en) | THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER | |
| DOP2011000343A (en) | PIRIDINE TIENO DERIVATIVES [2,3-B] AS VIRAL REPLICATION INHIBITORS | |
| MX2012007410A (en) | Novel antiviral compounds. | |
| EA201491479A1 (en) | DERIVATIVES OF LUPANOV TRITERPENOIDS AND THEIR PHARMACEUTICAL APPLICATIONS | |
| MX2022006940A (en) | PHARMACEUTICAL COMPOSITIONS. | |
| AR067184A1 (en) | USE OF 6- (3-CHLORO-2-FLUORBENCIL) -1 - [(2S) -1-HIDROXI-3-METILBUTAN-2-IL] -7-METOXI-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXILICO. PHARMACEUTICAL COMPOSITION | |
| ES2916649T1 (en) | Compositions and uses for the treatment of multiple sclerosis | |
| MX2020003055A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use. | |
| SI2932970T1 (en) | Antiviral therapy | |
| NZ741957A (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| CR20140540A (en) | NEW DOSAGE FORM AND FORMULATION OF ABEDITEROL | |
| EA200800467A1 (en) | APPLICATION OF COMPLEX ETHERS OF HYDROXYBENZOIC ACID AND ANALOGUES FOR OBTAINING MEDICINES FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTION | |
| JO3587B1 (en) | Oral dosage forms of bendamustine | |
| AR093476A1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECTODERMAL DYSPLASIA | |
| EP2593460A4 (en) | ANTI-VIRAL BENZYLAMIDE ANIMIRVENTS OF 4-OXO-4H-PYRIDO [L, 2-A] PYRIMIDINE-2-CARBOXYLIC ACID TO RADICALS NITROGEN IN POSITIONS 7 AND 9 | |
| CO2020000292A2 (en) | Combined medicinal preparation to treat viral infections | |
| DOP2022000004A (en) | PHARMACEUTICAL COMPOSITIONS RESISTANT TO THE DISCHARGE OF DOSES THAT INCLUDE VENIRUNAD | |
| UY33806A (en) | NOVEDOUS IMIDAZOQUINOLINE COMPOUNDS, COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY TLR7? | |
| MX350516B (en) | Nitrogen-containing fused ring compounds for use as crth2 antagonists. | |
| TH133837A (en) | ||
| RU2014116988A (en) | ALISPORIVIR FOR TREATING INFECTIONS CAUSED BY HEPATITIS C VIRUS | |
| EA202091320A1 (en) | LOCAL APPLICATION OF DIOXIDINE FOR INFECTIOUS INFLAMMATORY LESIONS OF THE EPITHELIUM | |
| AR117298A1 (en) | PEPTIDE BINDER | |
| RU2014140049A (en) | MOLECULE interferon-β-1a HUMAN pegylated, possess antiviral, immunomodulating and antiproliferative activity, with improved stability, reduced immunogenicity, improved pharmacokinetic and pharmacodynamic parameters suitable for medical applications, and immunobiological BEING ON ITS BASIS | |
| BR112015011179A8 (en) | stable aqueous pharmaceutical compositions comprising human insulin or an analogue or derivative thereof, their use and processes for their preparation |